Boehringer Receives Breakthrough Designation for AML Treatment

Boehringer Ingelheim Pharmaceuticals, Inc. is reporting that the FDA has granted Breakthrough Therapy designation to the company's investigational treatment for acute myeloid leukemia (AML).

That treatment is volasertib, an inhibitor of polo-like kinase (Plk). Boehringer is evaluating the treatment for patients aged 65 or older with previously untreated AML who are not eligible for intensive remission induction therapy.

Said Sabine Luik, M.D., senior vice president, Medicine & Regulatory Affairs, U.S. Regional Medical Director, Boehringer Ingelheim Pharmaceuticals, Inc.:

This FDA Breakthrough Therapy designation provides Boehringer Ingelheim the opportunity to engage in an ongoing dialogue with the FDA to help expedite the development of volasertib as a potential treatment option for these patients with AML. Volasertib is one of many investigational compounds in Boehringer Ingelheim's growing oncology pipeline and is an example of our commitment to exploring treatment approaches with the goal of improving patient outcomes.

Breakthrough Therapy designation is designed to streamline the development and review of drugs for serious or life-threatening conditions if preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.

A less intensive treatment

About one quarter of all adult leukemia diagnoses in the West are AML. It is an aggressive tumor of the bone marrow, and it is unlike other leukemias in that it does not enjoy a high rate of remission or cure.

This is especially true among older people, who are the ones typically diagnosed with AML. Because many can't withstand the intensive treatments, Boehringer began pursuing this treatment option.

According to the company,

Volasertib is designed to inhibit the activity of Plk1, an enzyme in the Plk family that regulates cell division (mitosis). This inhibition is intended to result in prolonged cell cycle arrest, ultimately leading to cell death (apoptosis).

Source: Boehringer

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap